Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
June 05, 2023 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to...
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
May 19, 2023 08:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
May 17, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol...
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
May 08, 2023 16:02 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
May 05, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
May 04, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
First quarter 2023 total revenue of $100.5 million, Crysvita® revenue of $76.0 million and Dojolvi® revenue of $14.3 million Total revenue grew 26% and Crysvita revenue grew 28% versus the first...
Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors
April 28, 2023 12:27 ET
|
Ultragenyx Pharmaceutical Inc.
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and...
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
April 27, 2023 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...